Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: Theory and practice

Journal of the National Cancer Institute

Volumn 96, Issue 13, 2004, Pages 990-997

  Parulekar, Wendy R ^a   Eisenhauer, Elizabeth A ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 DEDIMETHYLAMINOSANCYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CGP 69846A; ENDOSTATIN; ERLOTINIB; GEFITINIB; IMATINIB; ISIS 3521; L 778123; MARIMASTAT; MATUZUMAB; OBLIMERSEN; PELITINIB; REBIMASTAT; RG 83852; SEMAXANIB; SORAFENIB; SUNITINIB; TANOMASTAT; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB;

ALLERGIC PNEUMONITIS; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESEARCH; CARDIOTOXICITY; CLINICAL TRIAL; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG DOSE REGIMEN; DRUG TARGETING; HUMAN; MEDICAL LITERATURE; MOLECULAR DYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PUBLICATION; SIDE EFFECT; SOLID TUMOR; THEORY; TYPES OF STUDY; METHODOLOGY; NEOPLASM; PHASE 2 CLINICAL TRIAL; REVIEW;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; NEOPLASMS; RESEARCH DESIGN;

EID: 3242679103     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh182     Document Type: Article

References (84)

1. Eisenhauer EA, O'Dwyer PJ, Christian M, Humphrey JS. Phase I clinical trial design in cancer drug development. J Clin Oncol 2000;18:684-92.
2. Gelmon KA, Eisenhauer EA, Harris AL, Ratain MF, Workman P. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst 1999;91:1281-7.
3. Stadler WM, Ratain MJ. Development of target-based antineoplastic agents. Invest New Drugs 2000;18:7-16.
4. Ratain MJ, Stadler WM. Clinical trial designs for cytostatic agents. J Clin Oncol 2001;19:3154-5.
5. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 2001;19:265-72.
6. Parulekar WR, Eisenhauer EA. Novel endpoints and design of early clinical trials. Ann Oncol 2002;13 Suppl 4:139-43.
7. Adjei AA, Erlichman C, Davis JN, Cutler DL, Sloan JA, Marks RS, et al. A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res 2000;60:1871-7.
8. Awada A, Eskens FA, Piccart M, Cutler DL, van der Gaast A, Bleiberg H, et al.; EORTC Early Clinical Studies Group. Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. Eur J Cancer 2002;38:2272-8.
9. Awada A, Hendlisz A, Gil T, Munoz R, Bartholomeus S, de Valeriola D, et al. Final results of a clinical and pharmacokinetic (PK) phase I study of the Raf kinase inhibitor BAY 43-9006 in refractory solid cancers: a promising anti-tumor agent. Eur J Cancer 2002;38:S52.
10. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-14.
11. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20: 4292-302.
12. Brahmer JR, Kelsey S, Scigalla P, Hill G, Bello C, Elza-Brown K, et al. A phase I study of SU6668 in patients with refractory solid tumors [abstract]. Proc ASCO 2002;21:84a.
13. Britten CD, Rosen LS, Kabbinavar F, Rosen P, Mulay M, Hernandez, et al. Phase I trial of SU6668, a small molecule receptor tyrosine kinase inhibitor, given twice daily in patients with advanced cancers [abstract]. Proc ASCO 2002;21:28b.
14. Britten CD, Rowinsky EK, Soignet S, Patnaik A, Yao SL, Deutsch P, et al. A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. Clin Cancer Res 2001;7:3894-903.
15. Camacho LH, Soignet SL, Pezzulli S, Canales C, Aghajanian C, Spriggs DS, et al. Dose escalation study of oral farnesyl transferase inhibitor (FTI) BMS-214662 in patients with solid tumors [abstract]. Proc ASCO 2001; 20:79a.
16. Cropp G, Rosen Le, Mulay M, Langecker P, Hannah A. Pharmacokinetics and pharmacodynamics of SU5416 in a phase I, dose escalating trial in patients with advanced malignancies [abstract]. Proc ASCO 1999;18:161a.
17. Crul M, de Klerk GJ, Swart M, van't Veer LJ, de Jong D, Boerrigter L, et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2002;20:2726-35.
18. Cunningham CC, Holmlund JT, Schiller JH, Geary RS, Kwoh TJ, Dorr A, et al. A phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2000;6:1626-31.
19. Davis AJ, Gelmon KA, Siu LL, Moore MF, Britten CD, Mistry N, et al. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest New Drugs 2003;21:85-97.
20. Divgi CR, Welt S, Kris M, Real FX, Yeh SD, Gralla R, et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 1991;83:97-104.
21. Eder JP Jr, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002;20: 3772-84.
22. Erlichman C, Hidalgo M, Forero L, Boni J, Quinn S, Zacharchuk C, et al. EKB-569, an irreversible inhibitor of the epidermal growth factor receptor: phase I trial results in patients with advanced solid tumors. Eur J Cancer 2002;38:64.
23. Eskens FA, Awada A, Cutler DL, de Jonge MJ, Luyten GP, Faber MN, et al.; European Organization for Research and Treatment of Cancer Early Clinical Studies Group. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 2001;19:1167-75.
24. Forouzesh B, Buckner J, Adjei A, Marks R, Hammond L, Molpus K, et al. Phase I, bioavailability and pharmacokinetic study of oral dosage of CCI779 administered to patients with advanced solid malignancies. Eur J Cancer 2002;38:S54.
25. Gordon MS, Margolin K, Talpaz M, Sledge GW, Holmgren E Jr, Benjamin R, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-50.
26. Grochow L, O'Reilly S, Humphrey R, Sundaresan P, Donehower R, Sartorius S, et al. Phase I and pharmacokinetic study of the matrix metalloproteinase inhibitor (MMPI), BAY12-9566 [abstract]. Proc ASCO 1998; 17:213a.
27. Gupta E, Huang M, Mao Y, Patel R, Tarby C, Daniels R, et al. Pharmacokinetic evaluation of BMS-275291, a matrix metalloproteinase inhibitor in cancer patients [abstract]. Proc ASCO 2001;20:76a.
28. Heath EI, O'Reilly S, Humphrey R, Sundaresan P, Donehower RC, Sartorius S, et al. Phase I trial of the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced solid tumours. Cancer Chemother Pharmacol 2001;48:269-74.
29. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002;20:3792-803.
30. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002;20:3815-25.
31. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-79.
32. Hilger RA, Kredtke S, Hedley D, Moeller JG, Bauer RJ, Stellberg W, et al. Inhibition of ERK phosphorylation and clinical outcome in patients treated with the raf kinase inhibitor BAY 43-9006 [abstract]. Proc ASCO 2002; 21:27b.
33. Hirte H, Goel R, Major P, Seymour L, Huan S, Stewart D, et al. A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Ann Oncol 2000;11:1579-84.
34. Hirte H, Miller W, Major P, Goss G, Stewart D, Batist G, et al. Initial results of part 2 of a phase I/II pharmacokinetics, pharmacodynamic and biological activity study of ZD1839: NCIC CTG IND 122. Clin Cancer Res 2001;7:3761s.
35. Hirte H, Moore M, Hotte S, Oza A, Siu L, Harris H, et al. Final results of a phase I study of the raf-1 kinase inhibitor BAY 43-9006 in patients with advanced refractory solid tumours. Eur J Cancer 2002;38:55.
36. Hurwitz H, Humphrey J, Williams K, Ness E, Conway A, Lockhart AC, et al. A phase I trial of BMS-275291: a novel, non-hydroxamate, Sheddase-Sparing matrix metalloproteinase inhibitor (MMPI) with no dose limiting arthritis [abstract]. Proc ASCO 2001;20:98a.
37. Hurwitz H, Holden SN, Eckhardt SG, Rosenthal M, de Boer R, Rischin D, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signalling, in patients with solid tumors [abstract]. Proc ASCO 2002;21: 82a.
38. Kuenen B, Ruijter R, Hoekman K, Scigalla P, Giaccone G, Pinedo H. Dose finding study of SU6668 given thrice daily by oral route under fed conditions in patients with advanced malignancies [abstract]. Proc ASCO 2002; 21:110a.
39. LoRusso PM, Adjei AA, Meyer MB, Wozniak A, Gadgeel SM, Hanson LJ, et al. A phase I clinical and pharmacokinetic evaluation of the oral MEK inhibitor, CI-1040, administered for 21 consecutive days, repeated every 4 weeks in patients with advanced cancer [abstract]. Proc ASCO 2002;21: 81a.
40. Mitchell DY, Reid JM, Parchment RE, Meyer MB, Leopold JS, Herrera R, et al. Pharmacokinetics and pharmacodynamics of the oral MEK inhibitor, CI-1040, following multiple dose administration to patients with advanced cancer [abstract]. Proc ASCO 2002;21:81a.
41. Morimoto A, West KA, Yuen HA, Mathews WR, Bello C, Cropp GF, et al. Biomarker analysis of patient samples from a phase I clinical trial using the angiogenesis inhibitor, SU6668, for treatment of advanced solid tumors [abstract]. Proc ASCO 2002;21:85a.
42. Morris MJ, Tong WP, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF, et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002;8:679-83.
43. Negoro S, Nakagawa K, Fukuoka M, Kudoh S, Tamura T, Yoshimura N, et al. Final results of a phase I intermittent dose-escalation trial of ZD1839 ('Iressa') in Japanese patients with various solid tumours [abstract]. Proc ASCO 2001;20:324a.
44. Nemunaitis J, Holmlund JT, Kraynak M, Richards D, Bruce J, Ognoskie N, et al. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase c-alpha, in patients with advanced cancer. J Clin Oncol 1999;17:3586-95.
45. O'Donnell A, Trigo J, Banerji U, Raynaud F, Padhani A, Hannah A, et al. A phase I trial of the VEGF inhibitor SU5416, incorporating dynamic contrast MRI assessment of vascular permeability [abstract]. Proc ASCO 2000;19:177a.
46. Perez-Soler R, Donato NJ, Shin DM, Rosenblum MG, Zhang HZ, Tornos C, et al. Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852 [Erratum in: J Clin Oncol 1994;12:1526.]. J Clin Oncol 1994;12:730-9.
47. Punt CJ, van Maanen L, Bol CJ, Seifert WF, Wagener DJ. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anti-Cancer Drugs 2001;12:193-7.
48. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002;20:2240-50.
49. Raymond E, Faivre S, Vera K, Delbaldo C, Robert C, Spatz A, et al. for the SU11248 Working Group; Institute Gustave Roussy, Ville-juif, France; Pharmacia Co. and SUGEN Inc., Ville-juif, France. Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers [abstract]. Proc ASCO 2003;22:192.
50. Rosemurgy A, Harris J, Langleben A, Casper E, Goode S, Rasmussen H. Marimastat in patients with advanced pancreatic cancer: a dose finding study. Am J Clin Oncol 1999;22:247-52.
51. Rosen L, Mulay M, Mayers A, Kabbinavar F, Rosen P, Cropp G, et al. Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies [abstract]. Proc ASCO 1999;18:161a.
52. Rowinsky E, Humphrey R, Hammond LA, Aylesworth C, Smetzer L, Hidalgo M, et al. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol 2000;18:178-86.
53. Rubin R, Abbruzzese J, Morrison B, Mazina K, Lee Y, Zamek R, et al. Phase I trial of the farnesyl protein transferase (FPTase) inhibitor L-778123 on a 14- or 28-day dosing schedule [abstract]. Proc ASCO 2000;19:178a.
54. Rudek MA, Figg WD, Dyer V, Dahut W, Turner ML, Steinberg SM, et al. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 2001;19:584-92.
55. Rudin CM, Holmlund J, Fleming GF, Mani S, Stadler WM, Schumm P, et al. Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res 2001;7:1214-20.
56. Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Semin Oncol 1999;26:71-7.
57. Stevenson JP, Yao KS, Gallagher M, Friedland D, Mitchell EP, Cassella A, et al. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J Clin Oncol 1999;17:2227-36.
58. Stewart DJ, Donehower RC, Eisenhauer EA, Wainman N, Shah AK, Bonfils C, et al. A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann Oncol 2003;14:766-74.
59. Stopeck A, Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A. Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res 2002; 8:2798-805.
60. Strumberg D, Voliotis D, Moeller JG, Hilger RA, Richly H, Beling C, et al. A clinical phase I and biomarker study of the raf kinase inhibitor BAY 43-9006: preliminary evidence of activity in patients with advanced solid tumors. Eur J Cancer 2002;38:S53.
61. Tabernero J, Rojo F, Jimenez E, Montaner I, Snatome L, Guix M, et al. A phase I pharmacokinetic and serial tumor and skin pharmacodynamic study of weekly, every 2 weeks or every 3 weeks 1-hour infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor antibody, in patients with advanced tumours known to overexpress the EGFR. Eur J Cancer 2002;38:S69.
62. Tabernero J, Sonnichsen D, Albanell J, Damle B, Rojo F, Christopher L, et al. A phase I pharmacokinetic (PK) and serial tumor and PBMC pharmacodynamic (PD) study of weekly BMS-214662, a farnesyltransferase (FT) inhibitor, in patients with advanced solid tumors [abstract]. Proc ASCO 2001;20:77a.
63. Thomas A, Morgan B, Decatris A, Henry A, Pfister C, Gano C, et al. A phase I study of the oral vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 on a twice daily schedule in patients with advanced cancer. Eur J Cancer 2002;38:77.
64. Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003;21:223-31.
65. van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donato di Paola E, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38 Suppl 5:S83-7.
66. Voi M, Tabernero T, Cooper MR, Marimon I, Van Vreckem A, Albanell J, et al. A phase I study of the farnesyltransferase (FT) inhibitor BMS-214662 administered as a weekly 1-hour infusion in patients (pts) with advanced solid tumors: clinical findings [abstract]. Proc ASCO 2001;20:79a.
67. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F, et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000;18:1812-23.
68. Wojtowicz-Praga S, Torri J, Johnson M, Steen V, Marshall J, Ness E, et al. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 1998;16:2150-6.
69. Yuen AR, Halsey J, Fisher GA, Holmlund JT, Geary RS, Kwoh TJ, et al. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res 1999; 5:3357-63.
70. Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2000;18:927-41.
71. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003; 8:303-6.
72. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004;22:322-9.
73. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al. A phase II trial of ZD 1839 ('Iressa') in advanced non-small cell lung cancer patients who had failed platinum- and docetaxel-based regimens (IDEAL2) [abstract]. Proc ASCO 2002;21:292a.
74. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
75. Saltz L, Meropol NJ, Loehrer PJ, Waksal H, Needle MN, Mayer RJ. Single agent IMC-225 (Erbitux) has activity in CPT-11-refractory colorectal cancer that expresses the epidermal growth factor receptor [abstract]. Proc ASCO 2002;21:127a.
76. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
77. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-34.
78. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92.
79. Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. 2003. Available at: http://www.asco.org/hurwitz_no3646.
80. Miller KD, Rugo HS, Cobleigh MA, Marcom PK, Chap LI, Holmes FA, et al. Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastin) verus capecitabine alone in women with metastatic breast cancer previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 2002;76:36.
81. Van Cutsem E, Karasek P, Oettle H, Vervenne A, Szawlowski P, Schoffski P, et al. Phase III trial comparing gemcitabine plus R115777 (Zamestra versus gemcitabine plus placebo in advanced pancreatic cancer [abstract]. Proc ASCO 2002;21:130a.
82. Johnson DH, Herbst R, Giaccone G, Schiller J, Natale RB, Miller V, et al. ZD1839 (Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC): results from a phase III clinical trials (INTACT 2). Ann Oncol 2002;13(Suppl 5):127.
83. Giaconne G, Johnson DH, Manegold C, Scagliotti GV, Rosell R, Wolf M, et al. A phase III clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT 1). Ann Oncol 2002;13(Suppl 5):2.
84. Lynch TJ, Raju R, Lind M, Riviere A, Gatzemeier U, Drorr A, et al. Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: initial report [abstract]. Proc ASCO 2003;22:623.